Memantina Farmoz (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of neurodegenerative disorders, targeting the glutamatergic pathway in Alzheimer’s disease.

• Moderate to severe Alzheimer’s disease: improves cognition, daily functioning and overall clinical status.
• Mild‑to‑moderate Alzheimer’s disease (as add‑on therapy): may enhance benefits when combined with a cholinesterase inhibitor.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression in some patients.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory.

Memantina Farmoz may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements, may require dietary adjustment.
• Fatigue: feeling of tiredness or reduced energy.
• Hypertension: occasional increase in blood pressure.

Serious or Rare Side Effects

• Seizures: rare but may occur, particularly in patients with a seizure history.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing heart disease.
• Suicidal ideation: new or worsening thoughts of self‑harm.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: assess kidney function and consider dose adjustment.
• History of seizures: monitor closely for any seizure activity.
• Cardiovascular disease: observe blood pressure and heart rhythm regularly.
• Concomitant NMDA antagonists: avoid combined use to reduce neuropsychiatric risk.
• Pregnancy and lactation: safety not established; use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Farmoz can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can exacerbate central nervous system effects.
• Other NMDA antagonists: heightened risk of severe neuropsychiatric reactions.

Moderate Interactions (Monitor Closely)

• Antihypertensives: memantine may potentiate blood‑pressure‑lowering effects.
• CNS depressants (e.g., benzodiazepines): increased dizziness or sedation.
• Diuretics: may alter renal clearance of memantine, requiring dose review.